Zacks Investment Research upgraded shares of VWR Corporation (NASDAQ:VWR) from a hold rating to a buy rating in a research report sent to investors on Wednesday. They currently have $37.00 price target on the medical research company’s stock.

According to Zacks, “VWR’s second-quarter earnings report was quite impressive, with both the top and the bottom line beating the Zacks Consensus Estimate. Geographically, the company recorded growth in Americas during the reported quarter driven by strong sales of equipment and instrumentation. Management is also looking forward to the long-term synergy benefits from the proposed merger with Avantor. The merger is expected to strengthen VWR’s business across the Americas and Europe. While we await the merger to close in the fourth quarter of 2017 we note that the stock price has already reached close to Avantor’s offer price and hence the short-term upside potential of VWR is limited now. On the flip side, a drop in EMEA-APAC sales was disappointing. Moreover, foreign currency was a major dampener. VWR’s poor margin scenario also raises concern.”

A number of other research analysts have also commented on the stock. BidaskClub upgraded shares of VWR Corporation from a strong sell rating to a sell rating in a research note on Friday, August 11th. William Blair lowered shares of VWR Corporation from an outperform rating to a market perform rating in a research note on Friday, May 5th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $30.50.

VWR Corporation (VWR) opened at 33.11 on Wednesday. The firm’s 50-day moving average price is $33.00 and its 200 day moving average price is $30.97. VWR Corporation has a 52-week low of $24.42 and a 52-week high of $37.25. The firm has a market cap of $4.37 billion, a PE ratio of 30.66 and a beta of 1.19.

VWR Corporation (NASDAQ:VWR) last announced its quarterly earnings results on Monday, July 31st. The medical research company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.45 by $0.04. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the business earned $0.42 earnings per share. VWR Corporation’s revenue was up 2.2% compared to the same quarter last year. On average, equities analysts anticipate that VWR Corporation will post $1.87 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “VWR Corporation (VWR) Raised to “Buy” at Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/02/vwr-corporation-vwr-raised-to-buy-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in VWR Corporation by 4,641.8% in the first quarter. BlackRock Inc. now owns 4,072,333 shares of the medical research company’s stock worth $114,840,000 after buying an additional 3,986,452 shares in the last quarter. Shapiro Capital Management LLC bought a new position in VWR Corporation during the first quarter worth approximately $66,793,000. JPMorgan Chase & Co. raised its position in VWR Corporation by 79.2% in the first quarter. JPMorgan Chase & Co. now owns 4,531,105 shares of the medical research company’s stock worth $127,777,000 after buying an additional 2,002,306 shares in the last quarter. Harris Associates L P raised its position in VWR Corporation by 43.3% in the first quarter. Harris Associates L P now owns 5,250,960 shares of the medical research company’s stock worth $148,077,000 after buying an additional 1,587,214 shares in the last quarter. Finally, Earnest Partners LLC raised its position in VWR Corporation by 116.8% in the first quarter. Earnest Partners LLC now owns 1,797,102 shares of the medical research company’s stock worth $50,678,000 after buying an additional 968,313 shares in the last quarter.

About VWR Corporation

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.

Get a free copy of the Zacks research report on VWR Corporation (VWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related stocks with our FREE daily email newsletter.